Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01003938 · ClinicalTrials.gov registry record · Phase 2
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01003938 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 6 participants.
The verdict
NCT01003938, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy drug Hycamptin® (topotecan). Up to 30 patients will be enrolled in this study.
Interventions
- DRUG Topotecan
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01003938
The ClinicalTrials.gov registry entry for NCT01003938 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT01003938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01003938 about?
NCT01003938 is a clinical study titled "Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer". This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy drug Hycamptin® (topotecan). Up to 30 patients will be enrolled in this st...
What is the current status of trial NCT01003938?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-08. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01003938?
The interventions under investigation include: Topotecan (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01003938?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.